PL3177632T3 - Proleki inhibitora antygenu błony swoistego dla stercza (PSMA) - Google Patents
Proleki inhibitora antygenu błony swoistego dla stercza (PSMA)Info
- Publication number
- PL3177632T3 PL3177632T3 PL15829215T PL15829215T PL3177632T3 PL 3177632 T3 PL3177632 T3 PL 3177632T3 PL 15829215 T PL15829215 T PL 15829215T PL 15829215 T PL15829215 T PL 15829215T PL 3177632 T3 PL3177632 T3 PL 3177632T3
- Authority
- PL
- Poland
- Prior art keywords
- psma
- prodrugs
- inhibitor
- prostate specific
- specific membrane
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4084—Esters with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4087—Esters with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033926P | 2014-08-06 | 2014-08-06 | |
| PCT/US2015/044053 WO2016022827A1 (en) | 2014-08-06 | 2015-08-06 | Prodrugs of prostate specific membrane antigen (psma) inhibitor |
| EP15829215.1A EP3177632B1 (en) | 2014-08-06 | 2015-08-06 | Prodrugs of prostate specific membrane antigen (psma) inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3177632T3 true PL3177632T3 (pl) | 2022-06-13 |
Family
ID=55264571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15829215T PL3177632T3 (pl) | 2014-08-06 | 2015-08-06 | Proleki inhibitora antygenu błony swoistego dla stercza (PSMA) |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9988407B2 (pl) |
| EP (1) | EP3177632B1 (pl) |
| CA (1) | CA2961880C (pl) |
| CY (1) | CY1125201T1 (pl) |
| DK (1) | DK3177632T3 (pl) |
| ES (1) | ES2908411T3 (pl) |
| HR (1) | HRP20220446T1 (pl) |
| HU (1) | HUE058072T2 (pl) |
| LT (1) | LT3177632T (pl) |
| PL (1) | PL3177632T3 (pl) |
| PT (1) | PT3177632T (pl) |
| RS (1) | RS63082B1 (pl) |
| SI (1) | SI3177632T1 (pl) |
| WO (1) | WO2016022827A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3533473A3 (en) | 2013-11-14 | 2019-12-18 | Endocyte, Inc. | Compounds for positron emission tomography |
| CA2961575C (en) * | 2014-08-06 | 2023-09-19 | The Johns Hopkins University | Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors |
| PL3177632T3 (pl) | 2014-08-06 | 2022-06-13 | The Johns Hopkins University | Proleki inhibitora antygenu błony swoistego dla stercza (PSMA) |
| AU2018250609B2 (en) * | 2017-04-11 | 2024-05-09 | Adarga, Llc | Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy |
| CN112368024A (zh) | 2018-04-17 | 2021-02-12 | 恩多塞特公司 | 治疗癌症的方法 |
| GB201810965D0 (en) * | 2018-07-04 | 2018-08-15 | Univ College Cardiff Consultants Ltd | Phosphoantigen prodrug compounds |
| WO2020030954A1 (en) | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
| EP3853213A4 (en) * | 2018-09-21 | 2022-07-06 | Endocyte, Inc. | Shielding agents and their use |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| JP7798353B2 (ja) * | 2022-08-26 | 2026-01-14 | 国立研究開発法人農業・食品産業技術総合研究機構 | 細胞の生存を制御する方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| AU2002350623A1 (en) | 2001-10-26 | 2003-05-06 | The Scripps Research Institute | Targeted thrombosis by tissue factor polypeptides |
| US20060046978A1 (en) | 2004-08-31 | 2006-03-02 | Morphochem Ag | Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE) |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| CA2961575C (en) * | 2014-08-06 | 2023-09-19 | The Johns Hopkins University | Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors |
| PL3177632T3 (pl) | 2014-08-06 | 2022-06-13 | The Johns Hopkins University | Proleki inhibitora antygenu błony swoistego dla stercza (PSMA) |
-
2015
- 2015-08-06 PL PL15829215T patent/PL3177632T3/pl unknown
- 2015-08-06 HR HRP20220446TT patent/HRP20220446T1/hr unknown
- 2015-08-06 ES ES15829215T patent/ES2908411T3/es active Active
- 2015-08-06 PT PT158292151T patent/PT3177632T/pt unknown
- 2015-08-06 CA CA2961880A patent/CA2961880C/en active Active
- 2015-08-06 RS RS20220332A patent/RS63082B1/sr unknown
- 2015-08-06 US US15/502,105 patent/US9988407B2/en active Active
- 2015-08-06 LT LTEPPCT/US2015/044053T patent/LT3177632T/lt unknown
- 2015-08-06 HU HUE15829215A patent/HUE058072T2/hu unknown
- 2015-08-06 DK DK15829215.1T patent/DK3177632T3/da active
- 2015-08-06 SI SI201531827T patent/SI3177632T1/sl unknown
- 2015-08-06 EP EP15829215.1A patent/EP3177632B1/en active Active
- 2015-08-06 WO PCT/US2015/044053 patent/WO2016022827A1/en not_active Ceased
-
2018
- 2018-05-01 US US15/968,074 patent/US10544176B2/en active Active
-
2020
- 2020-01-24 US US16/751,556 patent/US11325931B2/en active Active
-
2022
- 2022-04-04 CY CY20221100255T patent/CY1125201T1/el unknown
- 2022-05-09 US US17/739,669 patent/US11932664B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230115651A1 (en) | 2023-04-13 |
| US20180244705A1 (en) | 2018-08-30 |
| US9988407B2 (en) | 2018-06-05 |
| EP3177632A4 (en) | 2018-04-04 |
| HRP20220446T1 (hr) | 2022-05-27 |
| RS63082B1 (sr) | 2022-04-29 |
| PT3177632T (pt) | 2022-03-21 |
| CY1125201T1 (el) | 2024-02-16 |
| CA2961880A1 (en) | 2016-02-11 |
| ES2908411T3 (es) | 2022-04-29 |
| SI3177632T1 (sl) | 2022-05-31 |
| US10544176B2 (en) | 2020-01-28 |
| CA2961880C (en) | 2022-09-27 |
| LT3177632T (lt) | 2022-04-25 |
| DK3177632T3 (da) | 2022-03-21 |
| US11325931B2 (en) | 2022-05-10 |
| EP3177632A1 (en) | 2017-06-14 |
| US11932664B2 (en) | 2024-03-19 |
| HUE058072T2 (hu) | 2022-07-28 |
| US20200399298A1 (en) | 2020-12-24 |
| US20170226141A1 (en) | 2017-08-10 |
| EP3177632B1 (en) | 2022-01-12 |
| WO2016022827A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
| PT3177632T (pt) | Pró-fármacos do inibidor de antígeno de membrana específica da próstata (psma) | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| PH12016501922A1 (en) | Substituted spirocyclic inhibitors of autotaxin | |
| GB201407267D0 (en) | Underwater surveys | |
| DK3191487T3 (da) | Spirocykliske cathepsin-c-inhibitorer | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| IN2015DE00625A (pl) | ||
| GB201405235D0 (en) | Improved plumbing apparatus | |
| IL248999A0 (en) | A method for geolocation | |
| GB201401005D0 (en) | Inhibitor | |
| GB2541309B (en) | Musical instruments | |
| IN2014CH00927A (pl) | ||
| IN2014MU03184A (pl) | ||
| GB201417347D0 (en) | Prodrugs of delanzomib | |
| GB201417348D0 (en) | Prodrugs of lxazomib | |
| GB201418154D0 (en) | Inhibitors | |
| GB201403344D0 (en) | Music | |
| HK1233952A1 (en) | Substituted spirocydic inhibitors of autotaxin | |
| GB201415292D0 (en) | Musical instruments | |
| GB201411017D0 (en) | Musical instruments | |
| GB201402839D0 (en) | Music teaching aid |